The price of tenofovir-emtricitabine undermines the cost-effectiveness and advancement of pre-exposure prophylaxis

AIDS

Volumn 25, Issue 18, 2011, Pages 2308-2310

  Keller, Samuel B ^a   Smith, Davey M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL;

COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH PRACTITIONER; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MEDICAID; PATIENT COUNSELING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS;

ADENINE; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; DRUG COSTS; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; MODELS, ECONOMIC; PHOSPHONIC ACIDS;

EID: 80855139785     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834d3cab     Document Type: Letter

References (12)

1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Pre-exposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599.
2. Truvada (Gilead Sciences). Red book 2010 Edition. Montvale, NJ: Thomson Reuters; 2010. p. 792.
3. Paltiel DA, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, et al. HIV pre-exposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 2009; 48:806-815.
4. Bonis PA, Wong JB. A short primer on cost-effectiveness analysis. 2011. http://www.uptodate.com/contents/a-shortprimer-on-cost-effectiveness-analysis. [Accessed 28 July 2011]
5. Freedberg KA, Losina E, Weinstein MC, Paltiel AD, Cohen CJ, Seage GR, et al. Cost-effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344: 824-831. (Pubitemid 32222162)
6. Walensky RP. Cost-effectiveness of HIV interventions: from cohort studies and clinical trials to policy. Top HIV Med 2009; 17:130-134.
7. Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med 2010; 153:778-789.
8. Milton W. How much are Americans willing to pay for a quality-adjusted life year? Medical Care 2008; 46:242-245.
9. Xia Q, Nonoyama A, Molitor F, Webb D, Osmond D. Recent decline in the incidence of human immunodeficiency virus infection among California men who have sex with men. Am J Epidemiol 2011; 174:203-210.
10. Lee DH, Vielemeyer O. Correspondence: pre-exposure chemoprophylaxis for HIV prevention. N Engl J Med 2011; 364:1372-1375.
11. Mayer, Kenneth H. Pre-exposure prophylaxis against HIV infection. 2011. http://www.uptodate.com/contents/preexposureprophylaxis-against-hiv-infection? source=search-result&selectedTitle=1-11. [Accessed 28 July 2011]
12. CDC. Interim Guidance: pre-exposure prophylaxis for the prevention in men who have sex with men. MMWR 2011; 55. http://www.cdc.gov/mmwr/preview/mmwrhtml/ mm6003a1. htm?s-cid=mm6003a1-w. [Accessed 28 July 2011]